1. RK-33

RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.

For research use only. We do not sell to patients.

RK-33 Chemical Structure

RK-33 Chemical Structure

CAS No. : 1070773-09-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
USD 66 In-stock
Solution
10 mM * 1 mL in DMSO USD 66 In-stock
Solid
5 mg USD 60 In-stock
10 mg USD 90 In-stock
25 mg USD 180 In-stock
50 mg USD 280 In-stock
100 mg USD 450 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE RK-33

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • Customer Review

Description

RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.

In Vitro

RK-33 shows inhibition of many kinds of cancer cells with IC50 of 3-6 µM, while PC3 is much less sensitive to RK-33 (IC50 >12 µM). RK-33 treatment causes a significant accumulation in the G1 phase for DU145 and LNCaP, although treatment with RK-33 causes only a moderate accumulation of the G1 phase for 22Rv1, and the treated cells have significantly reduced G2 phase. RK-33 treatment also causes 12 moderate G1 accumulation in 22Rv1[1]. RK-33-loaded NPs demonstrate cytotoxicity to MCF-7 cells in a dose-dependent manner, while equivalent doses of empty NPs have no killing effect. The IC50 value of 5% RK-33 loaded NPs is 49 μg/mL, and the IC50 value of 10% RK-33 loaded NPs is 25 μg/mL[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

There is more cell death (pyknotic or condensed nuclei) admixed with fibrin and interstitial edema in the tumors from mice from the combination RK-33 and radiation group compared to the control or single treatment groups. The treatment combination of RK-33 and radiation has an advantage in reducing tumor proliferation[1]. In the mice treated with RK-33-PLGA, RK-33 can be detected in the plasma (34 μg/mL) and liver (28 μg/g), but not lungs[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

428.44

Formula

C23H20N6O3

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1N(CC2=CC=C(OC)C=C2)C3=NC=NC4=C(N=CN4CC5=CC=C(OC)C=C5)C3=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (116.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3340 mL 11.6702 mL 23.3405 mL
5 mM 0.4668 mL 2.3340 mL 4.6681 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
Cell Assay
[2]

Briefly, 8×102 MCF-7 cells are seeded in a 96-well plate, and treated with different concentrations of RK-33 loaded nanoparticles and unloaded nanoparticles next day. After 72-h incubation, MTS reagent is added to the cells, and the absorbance is measured at 490 nm after 2-h incubation with MTS reagent. The experiment is repeated three independent times.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice are randomLy redistributed into four groups of eight according to their tumor growth, which results in an approximately equal distribution of tumor size at the beginning of radiation and RK-33 drug treatment. The four groups of mice are blindly chosen for four different experimental procedures, including control (injection of DMSO only), RK-33 treatment (injection of RK-33 only 50 mg/kg), radiation (one-time radiation of 5 Gy), or radiation and RK-33 treatment (combination of radiation of 5 Gy and RK-33 injection). RK-33 and DMSO are injected intraperitoneally thrice weekly for two weeks. Radiation is performed at the beginning of drug injection using the Small Animal Radiation Research Platform (SARRP) with a circular beam of 1 cm diameter, focusing on the tumor site. Mice of each group are euthanized 0 h and 24 h after radiation and tumors are extracted for γH2AX, cleaved Caspase 3, and Ki67 staining. The remaining mice of each group are imaged with a Xenogen IVIS Spectrum, with injection of D-luciferin 5 minutes before imaging. Mice are euthanized after six weeks of imaging and tumors are extracted for H&E staining, cleaved Caspase 3, and i67 staining. Morphology of the tumors after RK-33 and radiation treatment is assessed by a veterinary pathologist on hematoxylin and eosin stained sections.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.3340 mL 11.6702 mL 23.3405 mL 58.3512 mL
5 mM 0.4668 mL 2.3340 mL 4.6681 mL 11.6702 mL
10 mM 0.2334 mL 1.1670 mL 2.3340 mL 5.8351 mL
15 mM 0.1556 mL 0.7780 mL 1.5560 mL 3.8901 mL
20 mM 0.1167 mL 0.5835 mL 1.1670 mL 2.9176 mL
25 mM 0.0934 mL 0.4668 mL 0.9336 mL 2.3340 mL
30 mM 0.0778 mL 0.3890 mL 0.7780 mL 1.9450 mL
40 mM 0.0584 mL 0.2918 mL 0.5835 mL 1.4588 mL
50 mM 0.0467 mL 0.2334 mL 0.4668 mL 1.1670 mL
60 mM 0.0389 mL 0.1945 mL 0.3890 mL 0.9725 mL
80 mM 0.0292 mL 0.1459 mL 0.2918 mL 0.7294 mL
100 mM 0.0233 mL 0.1167 mL 0.2334 mL 0.5835 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
RK-33
Cat. No.:
HY-100455
Quantity:
MCE Japan Authorized Agent: